


Group 2: Initial Course 1 (IC-1)



IC-1 consists of:

- Continuous oral prednisone (PRED) 40mg/m² daily in three divided doses for 4 weeks, tapering over a period of 2 weeks.
- Vinblastine (VBL) 6mg/m²/dose i.v. bolus on day 1 of weeks 1, 2, 3, 4, 5, 6.

(For dose modifications refer to **Section** Ошибка! Источник ссылки не найден.)

There will be a one week break in treatment after IC-1 whatever the next treatment step, allowing for the response assessment at week 6.

Further therapy depends on Response at week 6:

⇒ Patients with NAD proceed to **Group 2 Continuation therapy**.

⇒ Patients with **AD better** or **intermediate** proceed to Initial treatment **Course 2**

⇒ Patients with AD worse **in non-risk organs**, proceed to **STRATUM II**

⇒ Patients who develop risk organ involvement under systemic therapy (very unlikely scenario) have to proceed to **STRATUM III** or **STRATUM IV** depending on physician's choice or donor availability. Please discuss such unusual SS-LCH cases with your National Coordinator.